Treating Advanced Solid Tumors with Specific RAS Mutations
Treatment
Study for advanced solid tumors with specific KRAS or other RAS mutations
Clinicaltrials.gov identifier:NCT05379985
Phase 1/2
Study Contact Information:
For additional information, contact:
Revolution Medicines Study Director
📞 1-844-2-REVMED
📧 [email protected]
About the Study
This is a Phase 1/2 clinical trial studying an experimental drug called RMC-6236 in adults with advanced . The study is evaluating the safety of the drug, how the body processes it, and whether it can help shrink tumors.
RAS proteins help control how cells grow and divide. Changes (mutations) in genes that make RAS proteins can cause these proteins to send signals that allow cancer cells to grow and survive. Mutations in the KRAS, NRAS, and HRAS genes are found in several types of cancer, including pancreatic, colorectal, and non-small cell lung cancers.
RMC-6236 is an experimental designed to block active RAS proteins, including certain forms of KRAS, NRAS, and HRAS. By blocking these signals, the drug may slow or stop cancer cell growth.
This Study is Open To:
In order to participate, people must have the following:
- Have an advanced solid tumor confirmed by testing of a tumor sample, including pancreatic, colorectal, and non-small cell lung cancers.
- Have a specific KRAS G12 mutation for the dose-escalation group, or a RAS mutation for certain dose-expansion or optimization groups. Some study groups include people with pancreatic cancer that does not have a RAS mutation.
- Have not received cancer treatment or have received standard treatment appropriate for their cancer type and .
- Are fully active or able to do light activities and are up and about most of the day.
This Study is NOT Open To:
People who:
- Have a primary tumor of the brain or central nervous system.
- Have active brain metastases that have not been treated.
- Have a gastrointestinal condition that could prevent them from swallowing or absorbing the study drug.
- Have another unstable or significant medical condition that, in the study doctor's opinion, could make participation unsafe or prevent them from completing the study requirements.
What the Study Involves
- Participants will take the study drug, RMC-6236, by mouth once a day. The dose will depend on the group they are enrolled in and the phase of the study.
- Participants will have regular study visits and monitoring, which may include physical exams, blood tests, imaging scans, and tumor testing or biopsies.
Study Contact Information:
For additional information, contact:
Revolution Medicines Study Director
📞 1-844-2-REVMED
📧 [email protected]
Locations:
California
City: Orange RECRUITING
Facility: UC Irvine/Chao Family Comprehensive Cancer Center
Contact Info:
No contact info provided
City: Santa Monica RECRUITING
Facility: UCLA
Contact Info:
No contact info provided
Florida
City: Tampa RECRUITING
Facility: Moffitt Cancer Center
Contact Info:
No contact info provided
Georgia
City: Atlanta RECRUITING
Facility: Piedmont Healthcare
Contact Info:
No contact info provided
Louisiana
City: Baton Rouge RECRUITING
Facility: Mary Bird Perkins Cancer Center
Contact Info:
No contact info provided
Massachusetts
City: Boston RECRUITING
Facility: Dana Farber Cancer Institute
Contact Info:
No contact info provided
Maryland
City: Baltimore RECRUITING
Facility: Johns Hopkins University
Contact Info:
No contact info provided
New York
City: New York RECRUITING
Facility: Perlmutter Cancer Center at NYU Langone Health
Contact Info:
No contact info provided
City: New York RECRUITING
Facility: Memorial Sloan-Kettering Cancer Center
Contact Info:
No contact info provided
City: New York RECRUITING
Facility: Columbia University
Contact Info:
No contact info provided
Ohio
City: Cincinnati RECRUITING
Facility: Christ Hospital Cancer Center
Contact Info:
No contact info provided
City: Maumee RECRUITING
Facility: Taylor Cancer Research Center
Contact Info:
No contact info provided
Tennessee
City: Chattanooga RECRUITING
Facility: Tennessee Oncology
Contact Info:
No contact info provided
City: Nashville RECRUITING
Facility: Sarah Cannon Research Institute
Contact Info:
No contact info provided
Texas
City: Austin RECRUITING
Facility: University of Texas at Austin
Contact Info:
No contact info provided
City: Dallas RECRUITING
Facility: Mary Crowley Cancer Research
Contact Info:
No contact info provided
City: Houston RECRUITING
Facility: The University of Texas MD Anderson Cancer Center
Contact Info:
No contact info provided
City: San Antonio RECRUITING
Facility: Next Oncology
Contact Info:
No contact info provided
Utah
City: Salt Lake City RECRUITING
Facility: Huntsman Cancer Institute
Contact Info:
No contact info provided
Virginia
City: Fairfax RECRUITING
Facility: Next Oncology Virginia
Contact Info:
No contact info provided
Washington
City: Seattle RECRUITING
Facility: Virginia Mason Medical Center
Contact Info:
No contact info provided
Treatment
Study for advanced solid tumors with specific KRAS or other RAS mutations
Clinicaltrials.gov identifier:NCT05379985
Phase 1/2
Study Contact Information:
For additional information, contact:
Revolution Medicines Study Director
📞 1-844-2-REVMED
📧 [email protected]